[1] 李建,王美玉,高震雷.基于雷诺现象评分的个体化护理在系统性硬化症患者的应用[J].中国病案, 2024, 25(11): 96-98. DOI: 10.3969/j.issn.1672-2566.2024.11.031. [2] 侯月盈,段新旺,李芹,等.不同性别系统性硬化症患者的临床特点分析[J].中华内科杂志, 2022, 61(4): 403-408.DOI: 10.3760/cma.j.cn112138-20210825-00586. [3] 陈丽君.系统性硬化症伴重症雷诺现象致肢体缺血坏死患者的护理干预效果观察[J].实用心脑肺血管病杂志, 2020, 28(增刊1): 186-188. [4] van den Hoogen F, Khanna D, Fransen J, et al. 2013 classification criteria for systemic sclerosis: an American College of Rheumatology/European League against Rheumatism collaborative initiative[J]. Arthritis Rheum, 2013, 65(11): 2737-2747. DOI: 10.1002/art.38098. [5] 郑筱萸.中药新药临床研究指导原则(试行)[M].北京:中国医药科技出版社, 2002:112-114. [6] 黄译平,黄科昌.中国临床科研工作者对疼痛视觉模拟量表应用的文献分析[J].中华麻醉学杂志, 2024, 44(8): 985-990. DOI: 10.3760/cma.j.cn131073.20240224.00817. [7] van der Meulen M, Zamanipoor Najafabadi A H, Lobatto D J, et al. SF-12 or SF-36 in pituitary disease? Toward concise and comprehensive patient-reported outcomes measurements[J]. Endocrine, 2020, 70(1): 123-133. DOI: 10.1007/s12020-020-02384-4. [8] Besag F M C, Vasey M J, Roy S, et al. Raynaud syndrome associated with medication for attention-deficit/hyperactivity disorder: a systematic review[J]. CNS Drugs, 2025, 39(3): 213-241. DOI: 10.1007/s40263-024-01154-4. [9] 卞博,苗青,吴范武,等.温阳化浊通络方体外抑制HIF-1a/Foxm1/smad3信号通路改善系统性硬化病肺微血管损伤[J].中国药理学通报, 2024, 40(11): 2119-2123. DOI: 10.12360/CPB202405056. [10] 于伶,屠文震,薛鸾,等.活血化瘀方熏洗对系统性硬化症患者雷诺现象的疗效观察[J].中国中西医结合皮肤性病学杂志, 2022, 21(1): 40-43. DOI: 10.3969/j.issn.1672-0709.2022.01.008. [11] 于珍珍,刘俊兰.自理理论指导下护理干预对系统性硬化症患者负性心理及生活质量的影响[J].现代中西医结合杂志, 2021, 30(33): 3749-3752. DOI: 10.3969/j.issn.1008-8849.2021.33.024. [12] 郭克磊,李颖利,吕芹,等.温阳化浊通络方抑制FOXP3甲基化促进Treg增殖治疗系统性硬化病的作用机制[J].中华中医药杂志, 2022, 37(8): 4661-4665. |